Eli Lilly and Company $LLY Holdings Raised by EFG Asset Management North America Corp.

EFG Asset Management North America Corp. grew its stake in Eli Lilly and Company (NYSE:LLY) by 27.0% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 14,938 shares of the company’s stock after acquiring an additional 3,177 shares during the period. Eli Lilly and Company comprises 1.6% of EFG Asset Management North America Corp.’s investment portfolio, making the stock its 6th biggest holding. EFG Asset Management North America Corp.’s holdings in Eli Lilly and Company were worth $11,637,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Wealth Preservation Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the 1st quarter valued at approximately $27,000. Blume Capital Management Inc. raised its stake in shares of Eli Lilly and Company by 46.7% in the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after acquiring an additional 14 shares during the period. IMG Wealth Management Inc. purchased a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $35,000. Financial Gravity Asset Management Inc. purchased a new stake in Eli Lilly and Company during the 1st quarter worth approximately $40,000. Finally, TD Capital Management LLC increased its stake in Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after buying an additional 31 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Up 1.1%

Shares of Eli Lilly and Company stock opened at $906.51 on Wednesday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $935.63. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market capitalization of $857.98 billion, a P/E ratio of 59.25, a PEG ratio of 1.21 and a beta of 0.47. The company’s fifty day moving average is $788.17 and its two-hundred day moving average is $772.81.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same period last year, the firm posted $1.18 EPS. Eli Lilly and Company’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be paid a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Insider Transactions at Eli Lilly and Company

In related news, Director J Erik Fyrwald acquired 1,565 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gabrielle Sulzberger acquired 117 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the purchase, the director directly owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have acquired 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is owned by company insiders.

Analysts Set New Price Targets

LLY has been the topic of several recent research reports. Cantor Fitzgerald upped their target price on shares of Eli Lilly and Company from $925.00 to $985.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Berenberg Bank reaffirmed a “hold” rating and set a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. HSBC upped their target price on shares of Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday. Finally, Morgan Stanley lowered their price target on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a report on Friday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $940.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.